亚太药业
(002370)
| 流通市值：19.07亿 | | | 总市值：19.07亿 |
| 流通股本：6.09亿 | | | 总股本：6.09亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 112,712,517.95 | 420,643,619.24 | 301,858,122.44 | 221,137,723.58 |
| 营业收入 | 112,712,517.95 | 420,643,619.24 | 301,858,122.44 | 221,137,723.58 |
| 二、营业总成本 | 114,454,069.55 | 484,468,251.62 | 353,686,573.69 | 248,838,210.32 |
| 营业成本 | 75,876,115.38 | 285,645,963.97 | 199,916,120.53 | 141,481,589.75 |
| 税金及附加 | 1,216,517.1 | 6,138,725.83 | 5,030,273.01 | 3,438,043.01 |
| 销售费用 | 14,316,311 | 76,612,850.83 | 56,844,659.32 | 44,557,251.15 |
| 管理费用 | 13,198,118.31 | 60,846,849.85 | 48,552,304.58 | 31,744,792.68 |
| 研发费用 | 4,643,430.6 | 21,794,853.52 | 15,897,936.95 | 8,024,817.2 |
| 财务费用 | 5,203,577.16 | 33,429,007.62 | 27,445,279.3 | 19,591,716.53 |
| 其中:利息费用 | 8,929,217.04 | 47,457,830.49 | 38,134,383.35 | 26,385,495.79 |
| 其中:利息收入 | 3,730,714.88 | 14,049,318.06 | 10,709,268.44 | 6,811,771.56 |
| 加:公允价值变动收益 | -1,393,706.46 | 1,779,788.36 | 3,555,975.6 | 37,358.25 |
| 加:投资收益 | - | 2,034,199.38 | 2,071,912.37 | 1,437,025.89 |
| 资产处置收益 | - | 395,073.76 | 13,950.91 | 13,950.91 |
| 资产减值损失(新) | -872,535.6 | -7,565,815.83 | -5,398,319.98 | -5,398,319.98 |
| 信用减值损失(新) | 402,786.94 | -628,110.36 | -946,787.57 | -768,964.16 |
| 其他收益 | 397,564.04 | 4,356,206.68 | 3,239,744.59 | 1,091,005 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -3,207,442.68 | -63,453,290.39 | -49,291,975.33 | -31,288,430.83 |
| 加:营业外收入 | - | 51,964,724.65 | 52,108,197.4 | 52,082,997.4 |
| 减:营业外支出 | - | 75,111.84 | 1,022,440.84 | 1,022,440.84 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -3,207,442.68 | -11,563,677.58 | 1,793,781.23 | 19,772,125.73 |
| 减:所得税费用 | -209,055.97 | 313,288.34 | 533,396.32 | 5,603.72 |
| 六、净利润 | -2,998,386.71 | -11,876,965.92 | 1,260,384.91 | 19,766,522.01 |
| 持续经营净利润 | -2,998,386.71 | -11,876,965.92 | 1,260,384.91 | 19,766,522.01 |
| 归属于母公司股东的净利润 | -2,998,386.71 | -11,876,965.92 | 1,260,384.91 | 19,766,522.01 |
| (一)基本每股收益 | 0 | -0.02 | 0 | 0.04 |
| (二)稀释每股收益 | 0 | -0.02 | 0 | 0.04 |
| 九、综合收益总额 | -2,998,386.71 | -11,876,965.92 | 1,260,384.91 | 19,766,522.01 |
| 归属于母公司股东的综合收益总额 | -2,998,386.71 | -11,876,965.92 | 1,260,384.91 | 19,766,522.01 |
| 公告日期 | 2024-04-27 | 2024-03-30 | 2023-10-28 | 2023-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |